Konica Minolta, Inc.

Lederle (japan), Ltd.

Chugai Seiyaku Kabushiki Kaisha

Konica-minolta Holdings, Inc.

Takeshi Isoda

Yasuhiro Watanabe

Kensaku Takanashi

Tomonori Kaneko

Toshio Kumagai

Satoshi Tamai

Takao Abe

Chisato Sato

Ado Mihira

Yasushi Nakano

Kohsuke Gonda

Noriaki Ohuchi

Mika Watanabe

Hideki Gouda

Naoko Furusawa

Masaru Takahashi

Mitsuru Sekiguchi

Shin Nakayama

Yasuyuki Motokui

Kazuhiko Hayashi

Nao Noro

Yutaka Hatanaka

Yoshikazu Kurihara

Kenji Nishikawa

Takeshi Wada

The present invention provides: an aminocoumarin compound having a structure represented by the following formula (1); and an aminocoumarin compound-containing resin particle containing the aminocoumarin compound and a resin particle containing the aminocoumarin compound. In formula (1), Rs each independently represent a hydrogen atom or a methyl group, Q represents a sulfur atom, an oxygen atom, or N&#x2014;R, and Rrepresents a hydrogen atom or a methyl group. The aminocoumarin compound of the present invention is a fluorescent dye that has a longer excitation wavelength than a conventionally known sulfonated coumarin-based compound and is effectively excited at a wavelength of 475 nm or more, particularly at a wavelength around 500 nm. The aminocoumarin compound of the present invention is a fluorescent dye that is excited, for example, at a wavelength of 475 to 510 nm and can be observed in a green light emission region of 510 to 540 nm using the wavelength characteristic, and can be expected to be suitably utilized in immunostaining or the like.

Aminocoumarin compound, and aminocoumarin compound-containing resin particles

The present invention may provide phosphor-integrated nanoparticles whose precipitation and/or aggregation, particularly aggregation can be inhibited upon carrying out immunostaining therewith and which can thus be used for staining even after long-term storage without requiring a complicated operation, the phosphor-integrated nanoparticles preferrably maintaining excellent performance, such as staining properties, even after long-term storage. The phosphor-integrated nanoparticles of the present invention have an average sphericity (f) of 0.80 to 0.95 and preferably have an average circumference ratio (R) of 0.50 to 0.95. More preferably, the matrix of the particles contains an organic compound, the phosphor-integrated nanoparticles have an average particle size of 300 nm or less, and a biological component-binding molecule is bound on the particle

Phosphor-integrated nanoparticles used in fluorescence observation

Provided is at least one method of suppressing, in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS), nonspecific signals generated by nonspecific adsorption of contaminants contained in a sample to an SPFS sensor section (e.g., a primary antibody, a solid-phase layer and a metal thin film). At least one method relates to a method of suppressing nonspecific signals originating from contaminants in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS) (including cases where a receptor for a compound to be measured is used in place of a primary antibody), the method comprising performing at least one pretreatment.

Method for suppressing nonspecific signals from contaminants in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS)

There is provided a biological substance quantitation method of quantitating a biological substance in a sample stained with a staining reagent including a fluorescent particle encapsulating a fluorescent substance, based on a fluorescence of the fluorescent substance. The method includes inputting a fluorescent image representing expression of the biological substance in the sample by a fluorescent bright spot; and quantitating an expression amount of the biological substance based on a fluorescence of the fluorescent bright spot. The biological substance is a nucleoprotein expressed at a cell nucleus. The fluorescent particle binds to the biological substance through a primary antibody which is directed against the biological substance as an antigen.

Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program

The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.

Method for detecting lung squamous cell carcinoma

Provided are: a probe reagent which is capable of stably yielding a fluorescence signal in FISH while inhibiting non-specific adsorption by the use of a nucleic acid molecule having a smaller number of bases than a BAC probe; and FISH using the probe reagent. The probe reagent is for in situ hybridization and comprises: phosphor-integrated nanoparticles containing phosphors integrated therein; and a nucleic acid molecule having a prescribed nucleic acid sequence, which phosphor-integrated nanoparticles and nucleic acid molecule are bound with each other.

Probe reagent and fish using probe reagent

An object of the present invention is to provide: a staining agent for tissue staining which has an improved fluorescence signal evaluation accuracy; and a tissue staining kit comprising the staining agent. The staining agent for tissue staining contains, as a staining component, dye-resin particles comprising thermosetting resin particles and a fluorescent dye immobilized on the resin particles, wherein the resin particles contains a substituent having an electric charge opposite to that of the fluorescent dye and forms an ionic bond or a covalent bond with the fluorescent dye, and the dye-resin particles have a particle size variation coefficient of 15% or less.

Staining agent for staining tissue, production method for staining agent for staining tissue and tissue staining kit including staining agent for staining tissue

It is intended to provide a liposome preparation which is a liposome, has a lipid bilayer membrane composed of an inner membrane constituted by a lipid including one or more types of functional lipids (a lipid capable of chemically interacting with another compound such as a charged lipid, a polarizable lipid, a lipid-soluble lipid or a water-soluble lipid) and an outer membrane constituted by a lipid with or without including one or more types of functional lipids, and is characterized in that at least a condition that the amount of any one type of functional lipid contained in the inner membrane is larger than in the outer membrane is satisfied. The liposome preparation is suitable as a liposome for encapsulating a contrast agent (a neutral substance having a hydroxy group), siRNA (an anionic substance) having an anticancer activity or the like. Its encapsulation ratio of drug agents, dispersion stability, control release and the like have been improved.

Liposome and method for producing liposome

A quantitative determination method of a biological substance in a sample stained with a staining reagent comprising fluorescent particles each encapsulating a fluorescent substance and binding to a biological substance recognizing site. The method comprises inputting a fluorescent image obtained by photographing the sample, extracting a predetermined region from the fluorescent image to calculate an integrated luminance of the predetermined region, and counting the number of fluorescent particles contained in the predetermined region from the integrated luminance and the average luminance per fluorescent particle. The average luminance per fluorescent particle is calculated from a correlation between the number of fluorescent particles counted from an image of the fluorescent particles visualized and the luminance derived from fluorescent light from the fluorescent particles and calculated from a fluorescent image of a region identical to the region taken in the image from which the number of fluorescent particles is counted.

Biological substance quantitative determination method, image processing device, pathological diagnosis support system, and computer readable medium

An object of the present invention is to provide a method of measuring the amount of a compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin, which method is suitable for reduction of noise originating from impurities and determination of the exact amount of a target compound. The present invention provides a method of measuring the amount of a target compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin (including cases where a target compound-capturing substance other than an antibody is used as a ligand), the method containing adding a sugar chain compound which competes (crosses) with impurities contained in the biological sample in binding with the labeled lectin.

Immunoassay method less affected by impurities

An image processing device includes an input unit and an alignment unit. The input unit inputs a cell shape image and a fluorescence image. The cell shape image shows a shape of a cell in a tissue section. The fluorescence image shows expression of a specific protein as a fluorescent bright point in a region same as a region in the tissue section. The alignment unit aligns the cell shape image and the fluorescence image based on an information source detected in both the cell shape image and the fluorescence image.

Image processing device, pathological diagnosis support system, image processing program, and pathological diagnosis support method

A first embodiment of the invention relates to novel carbapenem compounds, (1R, 5S, 6S)-2-�1-(1,3-thiazolin-2-yl)azetidin-3-yl!thio-6-�(R)-1-hydroxy-ethyl!-1- methylcarbapen-2-em-3-carboxyic acid derivatives. These carbapenem compounds are represented by the following formula having a beta-coordinated methyl group introduced at the 1-position and a �1-(1,3-thia-zolin-2-yl)azetidin-3-yl!thio group introduced at the 2-position. ##STR1## In the formula, R is hydrogen; lower alkyl group which is unsubstituted or substituted by hydroxy, lower alkoxy or lower alkoxy-lower alkoxy group; group --COOR.sup.1 (R.sup.1 is hydrogen or lower alkyl group); or group --CONR.sup.2 R.sup.3 (R.sup.2 and R.sup.3 are, independently each other, hydrogen or lower alkyl), and Y is carboxy, --COO.sup..crclbar. or protected carboxy. These compounds are useful antibiotics for prevention and treatment of bacterial infections. The second embodiment of the invention relates to 3-mercapto-1-(1,3-thiazolin-2-yl)azetidine represented by the following formula and its acid addition salts ##STR2## and to the production process therefor. The above compounds are useful as intermediates for preparing carbapenem compounds, which have strong antibacterial activity, with convenience and high yield.

Sulfur-containing compounds method for their use and prodction

Novel carbapenem compounds, (1R,5S,6S)-2-�1-(1,3-thiazolin-2-yl)azetidin-3-yl!thio-6-�(R)-1-hydroxyeth yl!-1-methyl-carbapen-2-em-3-carboxyic acid derivatives. These carbapenem compounds are represented by the following formula having a beta-coordinated methyl group introduced at the 1-position and a �1-(1,3-thiazolin-2-yl)azetidin-3-yl!thio group introduced at the 2-position. ##STR1## In the formula, R is hydrogen; lower alkyl group which is unsubstituted or substituted by hydroxy, lower alkoxy or lower alkoxy-lower alkoxy group; group --COOR.sup.1 (R.sup.1 is hydrogen or lower alkyl group); or group --CONR.sup.2 R.sup.3 (R.sup.2 and R.sup.3 are, independently each other, hydrogen or lower alkyl), and

2-�1-(1,3-thiazolin-2-yl)azetidin-3-yl!thio-carbapenem derivatives

Novel carbapenem compounds, (1R,5S,6S)-2-[1-(1,3-thiazolin-2-yl)azetidin-3-yl]thio-6-[(R)-1-hydroxyeth yl]-1-methyl-carbapen-2-em-3 -carboxyic acid derivatives. These carbapenem compounds are represented by the following formula having a beta-coordinated methyl group introduced at the 1-position and a [1-(1,3-thiazolin-2-yl)azetidin-3-yl]thio group introduced at the 2-position. ##STR1## In the formula, R is hydrogen; lower alkyl group which is unsubstituted or substituted by hydroxy, lower alkoxy or lower alkoxy-lower alkoxy group; group --COOR.sup.1 (R.sup.1 is hydrogen or lower alkyl group); or group --CONR.sup.2 R.sup.3 (R.sup.2 and R.sup.3 are, independently each other, hydrogen or lower alkyl), and Y is carboxy, --COO.sup..crclbar. or protected carboxy. These compounds are useful antibiotics for prevention and treatment of bacterial infections.

Growing community of inventors

Sayama, Japan

Takeshi Isoda